Leerink Raises Merck Price Target to $105 on Pipeline Momentum

Leerink has raised its price target for Merck, citing momentum in the company's pipeline. The investment firm now expects Merck to reach $105 per share, up from its previous target of $93. This increase is based on Leerink's analysis of the company's progress in developing new treatments and therapies.

Merck's pipeline has been a major focus for investors, with several promising candidates in various stages of clinical trials. Leerink's analysts believe that these pipeline assets have significant potential to drive growth and revenue for the company.

The price target increase is based on backtested results, which show a strong performance for Merck over a specific period. However, it's essential to note that backtested results are not indicative of future actual results and may under- or over-compensate for market factors such as liquidity.